Study One:
MPI: Emmanuel Peprah, PhD
MPI: Obiageli Nnodu, MD
Managing Sickle Cell Disease through Increased Adoption of Hydroxyurea in Nigeria (ACCELERATE) Study
Sponsor: NIH (National Institutes of Health, USA)
Study Type: Pragmatic Implementation Study
Sites: 16 sites across Nigeria
Primary Objective
To evaluate the level of hydroxyurea (HU) adoption among healthcare providers of our task-sharing (SIM) intervention in Nigeria and determine if HU adoption improved patient-level Sickle Cell Disease management and outcomes.
iCTS Role: Trial Monitor